BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6894891)

  • 1. The effect of partial thyroidectomy for Graves' disease on serum long-acting thyroid stimulator protector (LATS-P).
    Hardisty CA; Talbot CH; Munro DS
    Clin Endocrinol (Oxf); 1981 Feb; 14(2):181-8. PubMed ID: 6894891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
    Hardisty CA; Fowles A; Munro DS
    J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
    Hardisty CA; Hanford L; Munro DS
    Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental transmission of thyroid-stimulating immunoglobulins.
    Dirmikis SM; Munro DS
    Br Med J; 1975 Jun; 2(5972):665-6. PubMed ID: 1173561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
    Hardisty CA; Hanford L; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
    Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
    J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.
    Hardisty CA; Fowles A; Munro DS
    Clin Endocrinol (Oxf); 1984 May; 20(5):597-605. PubMed ID: 6547647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
    Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
    J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between thyroid stimulating and tsh-binding inhibiting immunoglobulins of Graves' disease.
    Macchia E; Fenzi GF; Monzani F; Lippi F; Vitti P; Grasso L; Bartalena L; Baschieri L; Pinchera A
    Clin Endocrinol (Oxf); 1981 Aug; 15(2):175-82. PubMed ID: 6118213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting thyroid stimulator (LATS) in toxic nodular goitre, toxic adenoma and Graves' disease.
    Lamberg BA; Gordin A; Viherkoski M; Kvist G
    Acta Endocrinol (Copenh); 1969 Oct; 62(2):199-209. PubMed ID: 5394703
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS).
    Volpé R; Desbarats-Schonbaum ML; Schonbaum E; Row VV; Ezrin C
    Am J Med; 1969 Feb; 46(2):217-26. PubMed ID: 5818477
    [No Abstract]   [Full Text] [Related]  

  • 12. [LATS and Graves' disease].
    Gordon A
    Harefuah; 1971 May; 80(10):569-70. PubMed ID: 5171988
    [No Abstract]   [Full Text] [Related]  

  • 13. Urinary excretion of LATS in a patient with Graves' disease complicated by nephrotic syndrome.
    Kajita Y; Miyoshi Y; Hachiya T; Miyazaki T; Yoshimura M; Ijiichi H; Ochi Y
    Endocrinol Jpn; 1980 Dec; 27(6):727-32. PubMed ID: 6790269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of thyroid-stimulating antibody and long acting thyroid stimulator in relatives of Graves' disease patients.
    Banovac K; Zakarija M; McKenzie JM; Witte A; Sekso M
    J Clin Endocrinol Metab; 1981 Sep; 53(3):651-3. PubMed ID: 6790561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [LATS in Graves-Basedow disease].
    Nauman J; Nauman A
    Pol Arch Med Wewn; 1971; 46(3):315-21. PubMed ID: 5108058
    [No Abstract]   [Full Text] [Related]  

  • 16. Human thyroid adenyl cyclase-stimulating activity in immunoglobulin G of patients with Graves' disease.
    Orgiazzi J; Williams DE; Chopra IJ; Solomon DH
    J Clin Endocrinol Metab; 1976 Feb; 42(2):341-54. PubMed ID: 946604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Concentration of plasma in hyperthyroid patients for the detection of G immunoglobulins with LATS activity].
    Orgiazzi J; Rousset B; Mornex R
    Ann Endocrinol (Paris); 1972; 33(2):139-47. PubMed ID: 4678454
    [No Abstract]   [Full Text] [Related]  

  • 18. Does LATS cause hyperthyroidism in Graves' disease? (A review biased toward the affirmative).
    McKenzie JM
    Metabolism; 1972 Sep; 21(9):883-94. PubMed ID: 4115791
    [No Abstract]   [Full Text] [Related]  

  • 19. LATS protector and abnormal thyroid stimulation in diffuse toxic goitre.
    Stewart RD
    N Z Med J; 1975 Jan; 81(531):24. PubMed ID: 1055311
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hyperthyroidism and the "long acting thyroid stimulator" (LATS)].
    Studer H
    Schweiz Med Wochenschr; 1967 May; 97(19):622-3. PubMed ID: 5632362
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.